Interpace Biosciences Inc 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR Commission File Number: 000-24249 Interpace Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware22-2919486(State or other jurisdiction of(I.R.S. Employer Waterview Plaza, Suite 310, 2001 Route 46, Parsippany, NJ 07054(Address of principal executive offices and zip code) (855) 776-6419(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantwas required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging Growth Company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: ClassShares Outstanding May 1, 2026Common Stock, par value $0.01 per share27,700,904 INTERPACE BIOSCIENCES, INC.FORM 10-Q FOR PERIOD ENDED MARCH 31, 2026TABLE OF CONTENTS PART I - FINANCIAL INFORMATIONItem 1.Unaudited Interim Condensed Consolidated Financial StatementsCondensed Consolidated Balance Sheets at March 31, 2026 (unaudited) and December 31, 20253Condensed Consolidated Statements of Operations for the three-month periods ended March 31, 2026 and 2025(unaudited)4Condensed Consolidated Statements of Stockholders’ Equity for the three-month periods ended March 31, 2026 and2025 (unaudited)5Condensed Consolidated Statements of Cash Flows for the three-month periods ended March 31, 2026 and 2025(unaudited)6Notes to Unaudited Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16Item 3.Quantitative and Qualitative Disclosures About Market Risk21Item 4.Controls and Procedures22PART II - OTHER INFORMATIONItem 1.Legal Proceedings22Item 1A.Risk Factors22Item 2.Unregistered Sales of Equity Securities and Use of Proceeds22Item 3.Defaults Upon Senior Securities22Item 4.Mine Safety Disclosures22Item 5.Other Information22Item 6.Exhibits23Signatures242 INTERPACE BIOSCIENCES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share and per share data) INTERPACE BIOSCIENCES, INC.NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(Tabular information in thousands, except per share amounts) 1. OVERVIEW Nature of Business Interpace Biosciences, Inc. (“Interpace” or the “Company”) is a company that provides esoteric molecular diagnostic testing andpathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived high riskof cancer from clinical features. The Company develops and commercializes genomic tests and related first-line assays that canpersonalize medicine to help improve patient diagnosis and management. 2. BASIS OF PRESENTATION Theaccompanying unaudited interim condensed consolidated financial statements and related notes(the“Interim FinancialStatements”) should be read in conjunction with the consolidated financial statements of the Company and its wholly-ownedsubsidiaries (Interpace Diagnostics Lab Inc., Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC), and related notes asincluded in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities &Exchange Commission (“SEC”) on March 30, 2026 and as amended on April 30, 2026. The Interim Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles inthe United States (“GAA